Contribute Try STAT+ Today

The Food and Drug Administration is delaying its decision on Biogen’s closely watched Alzheimer’s drug aducanumab, requesting more evidence that the treatment can slow the cognitive decline associated with the disease, the company said Friday.

The FDA had promised to render a decision on the approval of aducanumab by March 7. The process is now being extended by three months to June 7, the company said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • How many individuals and families will continue to suffer during this 90 day extension?

    We need a President who could get the FDA to move faster.

    Oh, wait……….

Comments are closed.